Citation: | WANG Shaojie, LI Xiaojie, XU Zhimeng, YAN Kang, CHEN Xi, JIANG Zhenzhou, ZHANG Luyong. Improvement of emodin on acute fatty liver in mice[J]. Journal of China Pharmaceutical University, 2017, 48(1): 89-95. DOI: 10.11665/j.issn.1000-5048.20170114 |
[1] |
Hardwick JP,Osei-Hyiaman D,Wiland H,et al.PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase(CYP4)isozymes:implications for prevention of lipotoxicity in fatty liver disease[J].PPAR Res,2009,2009:952734.
|
[2] |
Portincasa P, Grattagliano I, Palmieri VO, et al. Nonalcoholic steatohepatitis:recent advances from experimental models to clinical management[J].Clin Biochem,2005,38(3):203-217.
|
[3] |
Xue J,Ding W,Liu Y.Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice[J].Fitoterapia,2010,81(3):173-177.
|
[4] |
Song P,Kim JH,Ghim J,et al.Emodin regulates glucose utilization by activating AMP-activated protein kinase[J].J Biol Chem,2013,288(8):5732-5742.
|
[5] |
Heo SK, Yun HJ, Park WH, et al. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase-and mitochondrial-dependent apoptosis[J].J Cell Biochem,2008,105(1):70-80.
|
[6] |
Wang CH, Gao ZQ, Ye B, et al. Effect of emodin on pancreatic fibrosis in rats[J].World J Gastroenterol,2007,13(3):378-382.
|
[7] |
Liu WH,Qi Y,Jia D.Research progress on experimental models of non-alcoholic fatty liver disease[J].Shanghai J Tradit Chin Med(上海中医药杂志),2015,49(3):95-97.
|
[8] |
Yoshizawa F,Mochizuki S,Doi M,et al.Ethionine-induced ATP depletion represses mTOR signaling in the absence of increases in AMP-activated protein kinase activity in the rat liver[J].Biosci Biotechnol Biochem,2009,73(9):1984-1988.
|
[9] |
Yu HY,Wang BL,Zhao J,et al.Protective effect of bicyclol on tetracycline-induced fatty liver in mice[J].Toxicology,2009,261(3):112-118.
|
[10] |
Choi YJ, Lee CH, Lee KY, et al. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice[J].Toxicol Sci,2015,145(2):273-282.
|
[11] |
BénichouC.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276.
|
[12] |
Kohjima M,Enjoji M,Higuchi N,et al.Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J].Int J Mol Med,2007,20(3):351-358.
|
[13] |
Raghow R,Yellaturu C,Deng X,et al.SREBPs:the crossroads of physiological and pathological lipid homeostasis[J].Trends Endocrinol Metab,2008,19(2):65-73.
|
[14] |
Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152.
|
[15] |
Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice[J].Cell Metab,2011,13(4):376-388.
|
1. |
安中原,冯白茹,申茹,张新忠,余巧. 双黄补温敏凝胶的制备及体外释放考察. 中医药导报. 2024(03): 75-79 .
![]() | |
2. |
张小军,黄山芩,郭潇涵,季梦菲,沈雁,陈大全,许颖. 复方碘口腔喷雾原位膜的制备及促口腔溃疡修复评价. 中国药科大学学报. 2024(06): 775-782 .
![]() | |
3. |
安中原,冯白茹,余巧,申茹. 原位凝胶的研究进展. 江西化工. 2023(01): 1-4 .
![]() |